The ALPS Medical Breakthroughs ETF (SBIO) is a passively managed healthcare ETF that tracks small-cap and mid-cap pharmaceutical and biotechnology stocks in Phase II or Phase III FDA clinical trials. With a 0.5% expense ratio, $243.54 million in assets, and 107 holdings, it has delivered 32.1% year-to-date returns and 82.83% over 12 months. However, it carries high risk with a beta of 0.74 and 30.54% standard deviation. The fund received a Zacks ETF Rank of 3 (Hold), with alternatives like VHT and XLV offering lower expense ratios.

CG Oncology announced that its CEO Arthur Kuan will participate in fireside chat presentations at the Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, and the Morgan Stanley Global Healthcare Conference on September 14, 2026. The company is a late-stage clinical biopharmaceutical firm developing immunotherapies for bladder cancer treatment.

Kuehn Law is investigating whether officers and directors of CG Oncology, Inc. breached fiduciary duties to shareholders through potential self-dealing. Long-term shareholders may be entitled to damages and corporate governance reforms. The law firm is seeking shareholders to participate in the investigation at no cost.

CG Oncology announced publication of Phase 3 BOND-003 Cohort C trial results for cretostimogene grenadenorepvec in treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The study demonstrated 75.5% complete response rates, median duration of response of 27.9 months, 89% bladder preservation at 12 months, and a favorable safety profile with no Grade 3+ adverse events.

CG Oncology announced positive Phase 2 results from CORE-008 Cohort CX evaluating intravesical cretostimogene combined with gemcitabine in high-risk BCG-exposed and BCG-unresponsive bladder cancer patients. The trial demonstrated high complete response rates (85.7-92.3%), high-grade event-free survival of 96.0% at 3 months and 89.5% at 6 months, with a favorable safety profile and no Grade 3+ treatment-related adverse events.

The oncology landscape is experiencing rapid regulatory advancement as precision medicine and genomics expand significantly. Multiple biotech companies are advancing cancer therapies toward accelerated FDA approvals in 2026, with the precision medicine market projected to grow from $138.67 billion in 2026 to $537.17 billion by 2035. Key developments include Oncolytics' pelareorep showing strong response rates in anal cancer, CG Oncology's Phase 3 trial ahead of schedule, Zentalis advancing azenosertib in ovarian cancer, ArriVent initiating a pivotal Phase 3 study for firmonertinib, and PDS Biotechnology gaining FDA alignment on trial endpoints.

CG Oncology announced that its Chairman & CEO Arthur Kuan and President & COO Ambaw Bellete will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The company is a late-stage clinical biopharmaceutical firm developing bladder-sparing therapeutics for bladder cancer patients, with recent data showing promising efficacy rates for its lead candidate cretostimogene grenadenorepvec in non-muscle invasive bladder cancer.

CG Oncology appointed Christina Rossi, an accomplished life sciences executive with 25 years of pharmaceutical experience, to its Board of Directors. Simultaneously, Simone Song resigned from the board, marking a leadership transition as the company prepares for potential FDA approval of its bladder cancer therapeutic.

CG Oncology initiated a rolling Biologics License Application for cretostimogene, a potential bladder cancer treatment, demonstrating promising 24-month complete response rates and completing enrollment in a Phase 3 clinical trial for non-muscle invasive bladder cancer.

Guggenheim initiated coverage on CG Oncology with a buy rating and $90 price target, highlighting the company's promising investigational drug for non-muscle invasive bladder cancer treatment.

CG Oncology reported promising 24-month results for cretostimogene, a potential bladder cancer treatment, showing a 41.8% complete response rate in high-risk non-muscle invasive bladder cancer patients unresponsive to previous treatments.

CG Oncology announced completion of enrollment in its Phase 3 PIVOT-006 study, comparing an innovative intravesical therapy for intermediate-risk non-muscle invasive bladder cancer, with over 360 patients enrolled across 90+ sites.